The SP isn't a good indicator for the progress made in pre-revenue biotechs like IPIX sometimes, but it can be and has been used as a scare tactic. The fundamentals are getting stronger as the trials advance to later phases. The BPs under the CNDAs are interested in the drugs and IPIX is in the process to provide them with trial data.
B-UP was a success and negotiations could be underway. Before you ask where is it, keep in mind that the trial ended just three months ago. B-OM should be next, then P and K-OC. Positive trial data will interest a potential partner, not the current SP.
Leo canceled the interim analysis to protect the trial integrity. I understand why people who want to see the trial fail are frustrated. If Leo and Dr. Menon co-founded IPIX just to take salaries, they wouldn't defer them for four years from 2010-2013.
News 
Market Data 
Discover 
